AstraZeneca names Rich Fante as president of US business
Nov 19, 2008 -- AstraZeneca (NYSE: AZN), a company engaged in the research, development, manufacturing and marketing of prescription medicines and a supplier for healthcare services, declared on 18 November that it has appointed Rich Fante as president of its US business. A Fante succeeds Tony Zook, who was recently named president of AstraZeneca's wholly owned biologics business, MedImmune. Zook currently serves as the CEO of AstraZeneca North America and head of global marketing. A Previously, Fante has served AstraZeneca for 13 years in various leadership roles, including vice president of primary care for the gastrointestinal and respiratory franchises, including NEXIUM (esomeprazole magnesium) and PULMICORT RESPULES (budesonide inhalation suspension). He was also appointed as the company's vice president, brand strategy & portfolio operations. He oversaw the development and execution of marketing strategies for all company brands in the United States.
ABOUT XPLOSIVESTOCKS.COM
XplosiveStocks.com is a leading stock website that provides free daily alerts on stocks that are moving up. Xplosivestocks.com also tracks small cap stocks that are on the brink of exploding. We also feature companies on our website with research report, analysis, and newsletters. To feature a company on our web site please contacts us at info@xplosivestocks.com.
XplosiveStocks.com is an independent electronic publication that provides information on selected publicly traded companies. XplosiveStocks.com is not a registered investment advisor or broker-dealer. XplosiveStocks.com's affiliates, officers, directors and employees may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.
XplosiveStocks.com may have been compensated for the stocks mentioned above. For more details on our compensations visit: http://www.xplosivestocks.com/Disclaimer.html This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and XplosiveStocks.com undertakes no obligation to update such statements.
CONTACT: XplosiveStocks.com e-mail: info@xplosivestocks.com WWW: http://www.xplosivestocks.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index